GW24-e0586 FLUPENTIXOL MELITRACEN COMBINED WITH ONDANSETRON IN PREVENTION OF NAUSEA AND VOMITING INDUCED BY CHEMOTHERAPY: RESULT OF A SINGLE CENTER

Objectives Nausea and Vomiting are the most common complaints for patients with haematological neoplasia during chemotherapy. The poor disease prognosis always cause people in anxiety and depression, which add patients’ discomforts. The aim of this study is to observe the effect of lupentixol melitracen combined with ondansetron on nausea and vomiting. Methods 105 patients with haematological neoplasia in the state of complete remmission were included in this study and self-controlled method was used. 30 minutes before infusion of chemotherapeutics, the patients received recommended-dose of single ondansetron during first consolidation chemotherapy cycle (single group) and lupentixol melitracen 1 piece combined with ondansetron (combined group) during the second one. For every patient, the chemotherapy regimen and dosage in the two groups were same. The incidence of nausea and vomiting was evaluated beofore, during and after chemotherapeutics infusion. Results Totally 97 patients could be evaluated. The incidence of nausea beofore, during and immediately after chemotherapeutics infusion was respectively 10.2%, 42.5%, 40.6% in the single group and 1.6%, 23.3%, 18.5% in the combined one, and the difference was significant between the two groups (P < 0.05). While the incidence of vomiting was respectively 0%, 21.8%, 23.5% and 0%, 19.6%, 24.7% in the two groups and the difference had no statistical significance (P > 0.05). Conclusions Flupentixol melitracen combined with ondansetron is more effective to prevent nausea than single ondansetron but no more effect for vomiting in our study.